Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Exicure ( (XCUR) ).
On January 16, 2026, Exicure completed the first contractual milestone under its collaboration with GPCR Therapeutics by finishing a Phase 2 clinical trial of its novel stem cell mobilizer, Burixafor (GPC‑100), and submitting the clinical study report to the U.S. Food and Drug Administration. The milestone triggers a $1 million payment to GPCR Therapeutics within 30 days and adjusts the future sublicensing income-sharing ratio, deepening Exicure’s economic participation in and long-term commitment to the program and signaling continued progress in its CXCR4 inhibitor development strategy.
The most recent analyst rating on (XCUR) stock is a Hold with a $6.00 price target. To see the full list of analyst forecasts on Exicure stock, see the XCUR Stock Forecast page.
Spark’s Take on XCUR Stock
According to Spark, TipRanks’ AI Analyst, XCUR is a Neutral.
The score is primarily constrained by weak financial performance (minimal revenue, ongoing net losses, and negative free cash flow), despite an improved balance sheet and reduced cash burn. Technicals are mixed with a modestly constructive intermediate trend but weakness versus the 200-day average, while valuation is not supported due to negative earnings and no dividend yield.
To see Spark’s full report on XCUR stock, click here.
More about Exicure
Exicure, Inc. is a biopharmaceutical company developing novel small-molecule therapies, including a stem cell mobilizer based on a CXCR4 inhibitor, targeting advanced treatments in partnership with GPCR Therapeutics Inc.
Average Trading Volume: 698,106
Technical Sentiment Signal: Sell
Current Market Cap: $39.14M
For an in-depth examination of XCUR stock, go to TipRanks’ Overview page.